FREMONT, Calif., Feb. 21 /PRNewswire/ -- ARYx Therapeutics, a private drug discovery and development company, today announced the appointment of Herm Rosenman to its board of directors. Mr. Rosenman is a long-time executive with significant experience in financial operations, initial public offerings, and SEC reporting. He will chair ARYx’s Audit Committee.
“We welcome Mr. Rosenman to our Board and Audit Committee and look forward to the financial expertise and operational guidance that he will bring to our organization,” said Paul Goddard, Ph.D., ARYx’s chairman and chief executive officer. “Herm’s considerable track record in building and managing successful companies will be of great value to ARYx.”
Rosenman is currently vice president and chief financial officer at Gen-Probe Incorporated, a position that he has held since 2001. In 2002, he successfully led Gen-Probe’s spin-off from Chugai Pharmaceutical Co., Ltd. and subsequent listing on the Nasdaq National Market. Prior to joining Gen-Probe, Rosenman was president and CEO of Ultra Acquisition Corp., a retail chain and consumer products manufacturer, from 1997 to 2000. He was president and CEO of RadNet Management, Inc., a large healthcare provider, from 1994 to 1997 and prior to that was chief financial officer for Rexene Corp., a Fortune 1000 company in the petrochemicals industry.
Rosenman is also a former partner at Coopers & Lybrand (now PricewaterhouseCoopers LLP) where he served numerous Fortune 1000 clients, principally in the pharmaceuticals and telecommunications industries.
Rosenman holds a B.B.A. in finance and accounting from Pace College (now Pace University) and an M.B.A. in finance from the Wharton School of the University of Pennsylvania. He is a director on the Board of Discovery Partners International, a drug discovery company, where he serves as Chairman of the Audit Committee and as a member of the Corporate Governance Committee.
“ARYx has made impressive progress with its clinical-stage drug portfolio and is well-positioned for future growth and achievement,” said Mr. Rosenman. “I look forward to contributing to the company’s success.”
With the addition of Mr. Rosenman, ARYx’s board of directors now totals eight members.
About ARYx Therapeutics Inc.
ARYx Therapeutics is a privately-held pharmaceutical research and development company focused on addressing safety concerns in well-established and commercially successful existing therapies through application of its proprietary ARYx RetroMetabolic (ARM(TM)) drug design. ARYx improves today’s drugs, making proven therapies safer. ARYx currently has three products in clinical trials. ARYx Therapeutics was founded in 1997 by Peter Milner and Pascal Druzgala. For more information on the company, please see the company’s web site at www.aryx.com.
ARYx Therapeutics
CONTACT: David Nagler, Vice President, Corporate Affairs of ARYxTherapeutics, +1-510-585-2200, ext. 211
